[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQFpw00VGLRec3tae4AcRzi7Yk-QJlNKTkEl1qTb3M30":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":33,"phaseBuckets":82,"rows":89},"Aarhus University Hospital",[4,6],"Aarhus University Hospital Skejby",349,false,92,6,6035797,25,284,[15,18,21,23,25,27,29,31],{"name":16,"count":17},"Coronary Artery Disease",19,{"name":19,"count":20},"Acute Lymphoblastic Leukemia",7,{"name":22,"count":20},"Myocardial Infarction",{"name":24,"count":20},"Quality of Life",{"name":26,"count":10},"Type 2 Diabetes",{"name":28,"count":10},"Ischemic Heart Disease",{"name":30,"count":10},"Metabolic Syndrome",{"name":32,"count":10},"Inflammation",[34,39,44,49,54,59,64,69,74,77],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05185258","Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","2024-01-15","Enstilar",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04601116","The MASTER Study (MAmmary Cancer STatin ER Positive Study)","2025-01-01","Atorvastatin 80 Mg Oral",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05377736","Thyroid Nodule Gene Sequencing in a Danish Population","2025-08-31","Molecular analyses",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05630586","Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke","2025-09","Semaglutide",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07044232","NICardipine for Fast Achievement of Systolic BP Targets in ICH","2025-12-31","Nicardipine",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05585983","INfluenza VaccInation To Mitigate typE 1 Diabetes","2026-05-01","Vaxigrip Tetra Sanofi Pasteur Europe",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07499349","Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment While Minimizing High Exposures That Impose Increased Risk of Side Effects Such as Hyperammonemia","2026-06-30","Erwinase PK-model for children and young adults with ALL",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06544473","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome","2026-12-31","17-beta estradiol",{"nctId":75,"briefTitle":76,"date":72,"intervention":73},"NCT06570460","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05655013","Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)","2027-02-01","Zoledronate",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,122,149,167,191,209,231,258,279,306,324,353,371,389,407,430,452,477,504,522,558,584,602,628,649,671,697,724,742,771,789,807,825,853,871,899,917,935,953,980,998,1023,1041,1066,1084,1114,1138,1164,1192,1217,1242,1260,1286,1309,1336,1354,1372,1397,1423,1448,1472,1496,1523,1541,1559,1583,1632,1658,1676,1700,1724,1751,1776,1804,1828,1853,1877,1895,1921,1946,1973,1991,2015,2041,2065,2089,2113],{"intervention":73,"totalTrials":91,"cells":92},2,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":120},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[],{"trials":103,"activeCount":91,"soonestReadout":72},[104,116],{"nctId":70,"briefTitle":71,"status":105,"phases":106,"primaryCompletion":72,"completion":72,"start":107,"enrollment":108,"conditions":109,"interventions":115},"RECRUITING",[87],"2021-11-29",50,[110,111,112,113,114],"Turner Syndrome","Hypogonadism; Ovarian","Hormone Replacement Therapy","Estrogen Replacement Therapy","Estrogen Deficiency",[73,73],{"nctId":75,"briefTitle":76,"status":105,"phases":117,"primaryCompletion":72,"completion":72,"start":107,"enrollment":108,"conditions":118,"interventions":119},[87],[110,111,112,113,114],[73,73],{"trials":121,"activeCount":95},[],{"intervention":123,"totalTrials":124,"cells":125},"Denosumab",1,{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":147},{"trials":127,"activeCount":95},[],{"trials":129,"activeCount":95},[],{"trials":131,"activeCount":95},[],{"trials":133,"activeCount":95},[],{"trials":135,"activeCount":124,"soonestReadout":140},[136],{"nctId":137,"briefTitle":138,"status":105,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT07271771","The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity",[87],"2027-03-01","2024-05-21",40,[144],"Osteoporosis",[123,146],"Saline",{"trials":148,"activeCount":95},[],{"intervention":146,"totalTrials":124,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":165},{"trials":152,"activeCount":95},[],{"trials":154,"activeCount":95},[],{"trials":156,"activeCount":95},[],{"trials":158,"activeCount":95},[],{"trials":160,"activeCount":124,"soonestReadout":140},[161],{"nctId":137,"briefTitle":138,"status":105,"phases":162,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":163,"interventions":164},[87],[144],[123,146],{"trials":166,"activeCount":95},[],{"intervention":58,"totalTrials":124,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":189},{"trials":170,"activeCount":95},[],{"trials":172,"activeCount":95},[],{"trials":174,"activeCount":95},[],{"trials":176,"activeCount":95},[],{"trials":178,"activeCount":124,"soonestReadout":57},[179],{"nctId":55,"briefTitle":56,"status":180,"phases":181,"primaryCompletion":57,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NOT_YET_RECRUITING",[87],"2027-12-31","2025-10-01",88,[186],"Intracerebral Haemorrhage",[58,188],"Glyceryl trinitrate",{"trials":190,"activeCount":95},[],{"intervention":188,"totalTrials":124,"cells":192},{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":207},{"trials":194,"activeCount":95},[],{"trials":196,"activeCount":95},[],{"trials":198,"activeCount":95},[],{"trials":200,"activeCount":95},[],{"trials":202,"activeCount":124,"soonestReadout":57},[203],{"nctId":55,"briefTitle":56,"status":180,"phases":204,"primaryCompletion":57,"completion":182,"start":183,"enrollment":184,"conditions":205,"interventions":206},[87],[186],[58,188],{"trials":208,"activeCount":95},[],{"intervention":63,"totalTrials":124,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":229},{"trials":212,"activeCount":95},[],{"trials":214,"activeCount":95},[],{"trials":216,"activeCount":95},[],{"trials":218,"activeCount":95},[],{"trials":220,"activeCount":124,"soonestReadout":62},[221],{"nctId":60,"briefTitle":61,"status":105,"phases":222,"primaryCompletion":62,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},[87],"2027-05-01","2022-12-14",100,[227],"Diabetes Mellitus, Type 1",[63],{"trials":230,"activeCount":95},[],{"intervention":38,"totalTrials":124,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":256},{"trials":234,"activeCount":95},[],{"trials":236,"activeCount":95},[],{"trials":238,"activeCount":95},[],{"trials":240,"activeCount":95},[],{"trials":242,"activeCount":124,"soonestReadout":37},[243],{"nctId":35,"briefTitle":36,"status":244,"phases":245,"primaryCompletion":37,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":255},"ACTIVE_NOT_RECRUITING",[87],"2026-07-15","2022-02-16",12,[250,251,252,253,254],"Psoriasis Vulgaris","Psoriasis","Skin Diseases","Skin Diseases, Papulosquamous","Skin and Connective Tissue Diseases",[38],{"trials":257,"activeCount":95},[],{"intervention":81,"totalTrials":124,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":277},{"trials":261,"activeCount":95},[],{"trials":263,"activeCount":95},[],{"trials":265,"activeCount":95},[],{"trials":267,"activeCount":95},[],{"trials":269,"activeCount":124,"soonestReadout":80},[270],{"nctId":78,"briefTitle":79,"status":244,"phases":271,"primaryCompletion":80,"completion":80,"start":272,"enrollment":273,"conditions":274,"interventions":276},[87],"2023-05-10",200,[275],"Osteoporosis, Postmenopausal",[81],{"trials":278,"activeCount":95},[],{"intervention":280,"totalTrials":124,"cells":281},"Duloxetine",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":304},{"trials":283,"activeCount":95},[],{"trials":285,"activeCount":95},[],{"trials":287,"activeCount":95},[],{"trials":289,"activeCount":95},[],{"trials":291,"activeCount":124,"soonestReadout":296},[292],{"nctId":293,"briefTitle":294,"status":105,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT06232473","Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder",[87],"2027-11-01","2029-11-01","2024-01-01",424,[301],"Functional Disorder",[280,303],"Benztropine Mesylate 0.5 MG and passive placebo RAP",{"trials":305,"activeCount":95},[],{"intervention":303,"totalTrials":124,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":322},{"trials":309,"activeCount":95},[],{"trials":311,"activeCount":95},[],{"trials":313,"activeCount":95},[],{"trials":315,"activeCount":95},[],{"trials":317,"activeCount":124,"soonestReadout":296},[318],{"nctId":293,"briefTitle":294,"status":105,"phases":319,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":320,"interventions":321},[87],[301],[280,303],{"trials":323,"activeCount":95},[],{"intervention":325,"totalTrials":124,"cells":326},"acetylsalicyclic acid",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":349,"NA":351},{"trials":328,"activeCount":95},[],{"trials":330,"activeCount":95},[],{"trials":332,"activeCount":95},[],{"trials":334,"activeCount":124,"soonestReadout":339},[335],{"nctId":336,"briefTitle":337,"status":105,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT07012629","A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)",[86],"2031-09-30","2040-01-01","2025-11-26",1652,[344],"Covert Brain Infarction",[325,346,347,348],"Clopidogrel","Rosuvastatin","Atorvastatin",{"trials":350,"activeCount":95},[],{"trials":352,"activeCount":95},[],{"intervention":346,"totalTrials":124,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":367,"NA":369},{"trials":356,"activeCount":95},[],{"trials":358,"activeCount":95},[],{"trials":360,"activeCount":95},[],{"trials":362,"activeCount":124,"soonestReadout":339},[363],{"nctId":336,"briefTitle":337,"status":105,"phases":364,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":365,"interventions":366},[86],[344],[325,346,347,348],{"trials":368,"activeCount":95},[],{"trials":370,"activeCount":95},[],{"intervention":347,"totalTrials":124,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":385,"NA":387},{"trials":374,"activeCount":95},[],{"trials":376,"activeCount":95},[],{"trials":378,"activeCount":95},[],{"trials":380,"activeCount":124,"soonestReadout":339},[381],{"nctId":336,"briefTitle":337,"status":105,"phases":382,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":383,"interventions":384},[86],[344],[325,346,347,348],{"trials":386,"activeCount":95},[],{"trials":388,"activeCount":95},[],{"intervention":348,"totalTrials":124,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":403,"NA":405},{"trials":392,"activeCount":95},[],{"trials":394,"activeCount":95},[],{"trials":396,"activeCount":95},[],{"trials":398,"activeCount":124,"soonestReadout":339},[399],{"nctId":336,"briefTitle":337,"status":105,"phases":400,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":401,"interventions":402},[86],[344],[325,346,347,348],{"trials":404,"activeCount":95},[],{"trials":406,"activeCount":95},[],{"intervention":43,"totalTrials":124,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":426,"NA":428},{"trials":410,"activeCount":95},[],{"trials":412,"activeCount":95},[],{"trials":414,"activeCount":95},[],{"trials":416,"activeCount":124,"soonestReadout":42},[417],{"nctId":40,"briefTitle":41,"status":105,"phases":418,"primaryCompletion":42,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":425},[86],"2035-01-01","2021-01-04",3360,[423,424],"Breast Cancer Female","Estrogen Receptor Positive Tumor",[43],{"trials":427,"activeCount":95},[],{"trials":429,"activeCount":95},[],{"intervention":53,"totalTrials":124,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":433,"activeCount":95},[],{"trials":435,"activeCount":95},[],{"trials":437,"activeCount":124,"soonestReadout":52},[438],{"nctId":50,"briefTitle":51,"status":105,"phases":439,"primaryCompletion":52,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},[85],"2027-12","2023-04-12",380,[444],"Acute Ischemic Stroke",[53],{"trials":447,"activeCount":95},[],{"trials":449,"activeCount":95},[],{"trials":451,"activeCount":95},[],{"intervention":453,"totalTrials":124,"cells":454},"Allogenic adipose derived mesenchymal stem cells",{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":456,"activeCount":95},[],{"trials":458,"activeCount":95},[],{"trials":460,"activeCount":124,"soonestReadout":465},[461],{"nctId":462,"briefTitle":463,"status":105,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":470},"NCT05933434","Allogenic Mesenchymal Stem Cell Intraarticular Injection for Knee Osteoarthritis Therapy",[84,85],"2030-10","2024-03-07",80,[469],"Knee Osteoarthritis",[453],{"trials":472,"activeCount":95},[],{"trials":474,"activeCount":95},[],{"trials":476,"activeCount":95},[],{"intervention":478,"totalTrials":124,"cells":479},"Cabergoline 0.5 MG",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":481,"activeCount":95},[],{"trials":483,"activeCount":95},[],{"trials":485,"activeCount":124,"soonestReadout":490},[486],{"nctId":487,"briefTitle":488,"status":105,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":496},"NCT07072910","Cabergoline for Episodic Migraine",[85],"2028-03-01","2028-09-01","2025-11-12",150,[495],"Migraine",[478,497],"Cabergoline 1 MG",{"trials":499,"activeCount":95},[],{"trials":501,"activeCount":95},[],{"trials":503,"activeCount":95},[],{"intervention":497,"totalTrials":124,"cells":505},{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":507,"activeCount":95},[],{"trials":509,"activeCount":95},[],{"trials":511,"activeCount":124,"soonestReadout":490},[512],{"nctId":487,"briefTitle":488,"status":105,"phases":513,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":514,"interventions":515},[85],[495],[478,497],{"trials":517,"activeCount":95},[],{"trials":519,"activeCount":95},[],{"trials":521,"activeCount":95},[],{"intervention":523,"totalTrials":91,"cells":524},"HepB mAb19",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":526,"activeCount":95},[],{"trials":528,"activeCount":91,"soonestReadout":533},[529,539],{"nctId":530,"briefTitle":531,"status":105,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT06668727","Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)",[84],"2027-08-26","2024-08-26",30,[537],"Hepatitis B",[523],{"nctId":540,"briefTitle":541,"status":105,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":549},"NCT07610772","Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With Chronic Hepatitis D Infection",[84],"2028-04-01","2026-04-23",15,[547,548],"Hepatitis D, Chronic","Hepatitis B Chronic Infection",[523],{"trials":551,"activeCount":95},[],{"trials":553,"activeCount":95},[],{"trials":555,"activeCount":95},[],{"trials":557,"activeCount":95},[],{"intervention":559,"totalTrials":124,"cells":560},"senicapoc",{"EARLY_PHASE1":561,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":562,"activeCount":124,"soonestReadout":567},[563],{"nctId":564,"briefTitle":565,"status":105,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},"NCT07284069","Senicapoc and Perampanel for Newly Diagnosed Glioblastoma",[83],"2028-11-01","2026-03-01",36,[571],"Glioblastoma",[559,573],"Perampanel",{"trials":575,"activeCount":95},[],{"trials":577,"activeCount":95},[],{"trials":579,"activeCount":95},[],{"trials":581,"activeCount":95},[],{"trials":583,"activeCount":95},[],{"intervention":573,"totalTrials":124,"cells":585},{"EARLY_PHASE1":586,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":587,"activeCount":124,"soonestReadout":567},[588],{"nctId":564,"briefTitle":565,"status":105,"phases":589,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":590,"interventions":591},[83],[571],[559,573],{"trials":593,"activeCount":95},[],{"trials":595,"activeCount":95},[],{"trials":597,"activeCount":95},[],{"trials":599,"activeCount":95},[],{"trials":601,"activeCount":95},[],{"intervention":603,"totalTrials":124,"cells":604},"high-dose calcium",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":606,"activeCount":95},[],{"trials":608,"activeCount":95},[],{"trials":610,"activeCount":95},[],{"trials":612,"activeCount":95},[],{"trials":614,"activeCount":95},[],{"trials":616,"activeCount":124,"soonestReadout":622},[617],{"nctId":618,"briefTitle":619,"status":620,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":493,"conditions":625,"interventions":627},"NCT07381998","Effects of Total Thyroid Removal on Parathyroid Function and Quality of Life","ENROLLING_BY_INVITATION",[88],"2027-07","2028-12","2026-01-01",[626,24],"Hypoparathyroidism Post-surgical",[603],{"intervention":68,"totalTrials":124,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":631,"activeCount":95},[],{"trials":633,"activeCount":95},[],{"trials":635,"activeCount":95},[],{"trials":637,"activeCount":95},[],{"trials":639,"activeCount":95},[],{"trials":641,"activeCount":124,"soonestReadout":67},[642],{"nctId":65,"briefTitle":66,"status":105,"phases":643,"primaryCompletion":67,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":648},[],"2028-01-30","2008-07-01",475,[19],[68],{"intervention":48,"totalTrials":124,"cells":650},{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":652,"activeCount":95},[],{"trials":654,"activeCount":95},[],{"trials":656,"activeCount":95},[],{"trials":658,"activeCount":95},[],{"trials":660,"activeCount":95},[],{"trials":662,"activeCount":124,"soonestReadout":47},[663],{"nctId":45,"briefTitle":46,"status":244,"phases":664,"primaryCompletion":47,"completion":665,"start":666,"enrollment":535,"conditions":667,"interventions":670},[88],"2027-01-18","2022-03-01",[668,669],"Thyroid Nodule (Diagnosis)","Thyroid Cancer",[48],{"intervention":672,"totalTrials":124,"cells":673},"Insulin Aspart",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":682,"NA":695},{"trials":675,"activeCount":95},[],{"trials":677,"activeCount":95},[],{"trials":679,"activeCount":95},[],{"trials":681,"activeCount":95},[],{"trials":683,"activeCount":95},[684],{"nctId":685,"briefTitle":686,"status":687,"phases":688,"primaryCompletion":689,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT00449839","Changes of the Infusion Rate in Insulin Pump Treatment","COMPLETED",[87],"2008-10","2007-04",10,[693],"Diabetes",[672],{"trials":696,"activeCount":95},[],{"intervention":698,"totalTrials":124,"cells":699},"Conventional alendronate",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":722},{"trials":701,"activeCount":95},[],{"trials":703,"activeCount":95},[],{"trials":705,"activeCount":95},[],{"trials":707,"activeCount":95},[],{"trials":709,"activeCount":95},[710],{"nctId":711,"briefTitle":712,"status":687,"phases":713,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT05325515","The Effect of Effervescent Alendronate on Bone Turnover",[87],"2022-09-01","2022-12-01","2021-10-01",64,[719],"Osteopenia or Osteoporosis",[698,721],"Effervescent and buffered alendronate",{"trials":723,"activeCount":95},[],{"intervention":721,"totalTrials":124,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":740},{"trials":727,"activeCount":95},[],{"trials":729,"activeCount":95},[],{"trials":731,"activeCount":95},[],{"trials":733,"activeCount":95},[],{"trials":735,"activeCount":95},[736],{"nctId":711,"briefTitle":712,"status":687,"phases":737,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":738,"interventions":739},[87],[719],[698,721],{"trials":741,"activeCount":95},[],{"intervention":743,"totalTrials":124,"cells":744},"Amlodipine",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":769},{"trials":746,"activeCount":95},[],{"trials":748,"activeCount":95},[],{"trials":750,"activeCount":95},[],{"trials":752,"activeCount":95},[],{"trials":754,"activeCount":95},[755],{"nctId":756,"briefTitle":757,"status":687,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":765},"NCT01180413","Intensive Vasodilator Therapy in Patients With Essential Hypertension",[87],"2012-04","2010-12",48,[763,764],"Essential Hypertension","High Blood Pressure",[743,766,767,768],"Ramipril","Lercanidipine","Losartan",{"trials":770,"activeCount":95},[],{"intervention":766,"totalTrials":124,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":781,"NA":787},{"trials":774,"activeCount":95},[],{"trials":776,"activeCount":95},[],{"trials":778,"activeCount":95},[],{"trials":780,"activeCount":95},[],{"trials":782,"activeCount":95},[783],{"nctId":756,"briefTitle":757,"status":687,"phases":784,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":785,"interventions":786},[87],[763,764],[743,766,767,768],{"trials":788,"activeCount":95},[],{"intervention":767,"totalTrials":124,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":797,"PHASE4":799,"NA":805},{"trials":792,"activeCount":95},[],{"trials":794,"activeCount":95},[],{"trials":796,"activeCount":95},[],{"trials":798,"activeCount":95},[],{"trials":800,"activeCount":95},[801],{"nctId":756,"briefTitle":757,"status":687,"phases":802,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":803,"interventions":804},[87],[763,764],[743,766,767,768],{"trials":806,"activeCount":95},[],{"intervention":768,"totalTrials":124,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":823},{"trials":810,"activeCount":95},[],{"trials":812,"activeCount":95},[],{"trials":814,"activeCount":95},[],{"trials":816,"activeCount":95},[],{"trials":818,"activeCount":95},[819],{"nctId":756,"briefTitle":757,"status":687,"phases":820,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":821,"interventions":822},[87],[763,764],[743,766,767,768],{"trials":824,"activeCount":95},[],{"intervention":826,"totalTrials":124,"cells":827},"Remifentanil",{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":836,"NA":851},{"trials":829,"activeCount":95},[],{"trials":831,"activeCount":95},[],{"trials":833,"activeCount":95},[],{"trials":835,"activeCount":95},[],{"trials":837,"activeCount":95},[838],{"nctId":839,"briefTitle":840,"status":687,"phases":841,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":849},"NCT02053818","Remifentanil\u002FSufentanil for CABG+\u002F-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.",[87],"2015-06","2015-08","2011-08",60,[847,848],"Ischaemic Heart Disease","Aortic Stenosis",[826,850],"Sufentanil",{"trials":852,"activeCount":95},[],{"intervention":850,"totalTrials":124,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":869},{"trials":856,"activeCount":95},[],{"trials":858,"activeCount":95},[],{"trials":860,"activeCount":95},[],{"trials":862,"activeCount":95},[],{"trials":864,"activeCount":95},[865],{"nctId":839,"briefTitle":840,"status":687,"phases":866,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":867,"interventions":868},[87],[847,848],[826,850],{"trials":870,"activeCount":95},[],{"intervention":872,"totalTrials":124,"cells":873},"Sufentanil I",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":897},{"trials":875,"activeCount":95},[],{"trials":877,"activeCount":95},[],{"trials":879,"activeCount":95},[],{"trials":881,"activeCount":95},[],{"trials":883,"activeCount":95},[884],{"nctId":885,"briefTitle":886,"status":687,"phases":887,"primaryCompletion":888,"completion":889,"start":890,"enrollment":845,"conditions":891,"interventions":893},"NCT02756598","Stress, Anxiety and Type A Personality and Analgesics",[87],"2018-01-01","2018-06-30","2015-01",[892],"Postoperative; Dysfunction Following Cardiac Surgery",[872,894,895,896],"Sufentanil II","Propofol I","Propofol II",{"trials":898,"activeCount":95},[],{"intervention":894,"totalTrials":124,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":909,"NA":915},{"trials":902,"activeCount":95},[],{"trials":904,"activeCount":95},[],{"trials":906,"activeCount":95},[],{"trials":908,"activeCount":95},[],{"trials":910,"activeCount":95},[911],{"nctId":885,"briefTitle":886,"status":687,"phases":912,"primaryCompletion":888,"completion":889,"start":890,"enrollment":845,"conditions":913,"interventions":914},[87],[892],[872,894,895,896],{"trials":916,"activeCount":95},[],{"intervention":895,"totalTrials":124,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":933},{"trials":920,"activeCount":95},[],{"trials":922,"activeCount":95},[],{"trials":924,"activeCount":95},[],{"trials":926,"activeCount":95},[],{"trials":928,"activeCount":95},[929],{"nctId":885,"briefTitle":886,"status":687,"phases":930,"primaryCompletion":888,"completion":889,"start":890,"enrollment":845,"conditions":931,"interventions":932},[87],[892],[872,894,895,896],{"trials":934,"activeCount":95},[],{"intervention":896,"totalTrials":124,"cells":936},{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":943,"PHASE4":945,"NA":951},{"trials":938,"activeCount":95},[],{"trials":940,"activeCount":95},[],{"trials":942,"activeCount":95},[],{"trials":944,"activeCount":95},[],{"trials":946,"activeCount":95},[947],{"nctId":885,"briefTitle":886,"status":687,"phases":948,"primaryCompletion":888,"completion":889,"start":890,"enrollment":845,"conditions":949,"interventions":950},[87],[892],[872,894,895,896],{"trials":952,"activeCount":95},[],{"intervention":954,"totalTrials":124,"cells":955},"Rifapentine",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":978},{"trials":957,"activeCount":95},[],{"trials":959,"activeCount":95},[],{"trials":961,"activeCount":95},[],{"trials":963,"activeCount":95},[],{"trials":965,"activeCount":95},[966],{"nctId":967,"briefTitle":968,"status":969,"phases":970,"primaryCompletion":971,"completion":971,"start":972,"enrollment":973,"conditions":974,"interventions":976},"NCT03266991","Treatment of Latent Tuberculosis in Socially Marginalised Citizens","TERMINATED",[87],"2023-02-09","2017-10-27",22,[975],"Compliance, Patient",[954,977],"Isoniazid",{"trials":979,"activeCount":95},[],{"intervention":977,"totalTrials":124,"cells":981},{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":988,"PHASE4":990,"NA":996},{"trials":983,"activeCount":95},[],{"trials":985,"activeCount":95},[],{"trials":987,"activeCount":95},[],{"trials":989,"activeCount":95},[],{"trials":991,"activeCount":95},[992],{"nctId":967,"briefTitle":968,"status":969,"phases":993,"primaryCompletion":971,"completion":971,"start":972,"enrollment":973,"conditions":994,"interventions":995},[87],[975],[954,977],{"trials":997,"activeCount":95},[],{"intervention":999,"totalTrials":124,"cells":1000},"Brodalumab",{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1009,"NA":1021},{"trials":1002,"activeCount":95},[],{"trials":1004,"activeCount":95},[],{"trials":1006,"activeCount":95},[],{"trials":1008,"activeCount":95},[],{"trials":1010,"activeCount":95},[1011],{"nctId":1012,"briefTitle":1013,"status":1014,"phases":1015,"primaryCompletion":1016,"completion":1016,"start":1017,"enrollment":108,"conditions":1018,"interventions":1019},"NCT03478280","Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis","UNKNOWN",[87],"2020-03-15","2018-09-15",[251],[999,1020],"Placebos",{"trials":1022,"activeCount":95},[],{"intervention":1020,"totalTrials":124,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1039},{"trials":1026,"activeCount":95},[],{"trials":1028,"activeCount":95},[],{"trials":1030,"activeCount":95},[],{"trials":1032,"activeCount":95},[],{"trials":1034,"activeCount":95},[1035],{"nctId":1012,"briefTitle":1013,"status":1014,"phases":1036,"primaryCompletion":1016,"completion":1016,"start":1017,"enrollment":108,"conditions":1037,"interventions":1038},[87],[251],[999,1020],{"trials":1040,"activeCount":95},[],{"intervention":1042,"totalTrials":124,"cells":1043},"Tenofovir disoproxil fumarate",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1064},{"trials":1045,"activeCount":95},[],{"trials":1047,"activeCount":95},[],{"trials":1049,"activeCount":95},[],{"trials":1051,"activeCount":95},[],{"trials":1053,"activeCount":95},[1054],{"nctId":1055,"briefTitle":1056,"status":687,"phases":1057,"primaryCompletion":1058,"completion":1058,"start":1059,"enrollment":142,"conditions":1060,"interventions":1062},"NCT00647244","Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients",[87],"2010-08","2008-06",[1061],"HIV Infections",[1042,1063],"Abacavir",{"trials":1065,"activeCount":95},[],{"intervention":1063,"totalTrials":124,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1082},{"trials":1069,"activeCount":95},[],{"trials":1071,"activeCount":95},[],{"trials":1073,"activeCount":95},[],{"trials":1075,"activeCount":95},[],{"trials":1077,"activeCount":95},[1078],{"nctId":1055,"briefTitle":1056,"status":687,"phases":1079,"primaryCompletion":1058,"completion":1058,"start":1059,"enrollment":142,"conditions":1080,"interventions":1081},[87],[1061],[1042,1063],{"trials":1083,"activeCount":95},[],{"intervention":1085,"totalTrials":124,"cells":1086},"Phenylephrine",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1112},{"trials":1088,"activeCount":95},[],{"trials":1090,"activeCount":95},[],{"trials":1092,"activeCount":95},[],{"trials":1094,"activeCount":95},[],{"trials":1096,"activeCount":95},[1097],{"nctId":1098,"briefTitle":1099,"status":687,"phases":1100,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":535,"conditions":1104,"interventions":1111},"NCT04419662","Evaluation of Patients After Cardiac Surgery: Novel Ultrasound Parameters for Quantification of Renal Perfusion & Analysis of Phenylephrines' Effect on Invasive Haemodynamics and Echocardiographic Measures",[87],"2021-05-30","2021-05-31","2020-05-25",[1105,1106,1107,1085,1108,1109,1110],"Ultrasonography, Renal","Cardiac Surgery","Hemodynamics","Renal Perfusion","Echocardiography","Anesthesia",[1085],{"trials":1113,"activeCount":95},[],{"intervention":1115,"totalTrials":124,"cells":1116},"Zoledronic Acid",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1125,"NA":1136},{"trials":1118,"activeCount":95},[],{"trials":1120,"activeCount":95},[],{"trials":1122,"activeCount":95},[],{"trials":1124,"activeCount":95},[],{"trials":1126,"activeCount":95},[1127],{"nctId":1128,"briefTitle":1129,"status":687,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1135},"NCT03087851","Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis",[87],"2020-08-01","2017-03-13",61,[144],[1115],{"trials":1137,"activeCount":95},[],{"intervention":1139,"totalTrials":124,"cells":1140},"Amiodarone",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1162},{"trials":1142,"activeCount":95},[],{"trials":1144,"activeCount":95},[],{"trials":1146,"activeCount":95},[],{"trials":1148,"activeCount":95},[],{"trials":1150,"activeCount":95},[1151],{"nctId":1152,"briefTitle":1153,"status":1014,"phases":1154,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1161},"NCT00724581","Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer",[87],"2009-08","2009-12","2008-08",275,[1160],"Atrial Fibrillation",[1139],{"trials":1163,"activeCount":95},[],{"intervention":1165,"totalTrials":124,"cells":1166},"Grass pollen extract - Alutard Phleum pratense, ALK",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1188,"NA":1190},{"trials":1168,"activeCount":95},[],{"trials":1170,"activeCount":95},[],{"trials":1172,"activeCount":95},[],{"trials":1174,"activeCount":95},[1175],{"nctId":1176,"briefTitle":1177,"status":687,"phases":1178,"primaryCompletion":1179,"completion":1180,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1187},"NCT05191186","Documentation of Efficacy of Intralymphatic Allergen Immunotherapy",[86],"2023-08-01","2023-12-31","2020-02-01",450,[1184,1185,1186],"Allergic Rhinitis Due to Grass Pollen","Allergic Conjunctivitis of Both Eyes","Allergic Asthma",[1165],{"trials":1189,"activeCount":95},[],{"trials":1191,"activeCount":95},[],{"intervention":1193,"totalTrials":124,"cells":1194},"Actilyse",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1213,"NA":1215},{"trials":1196,"activeCount":95},[],{"trials":1198,"activeCount":95},[],{"trials":1200,"activeCount":95},[],{"trials":1202,"activeCount":95},[1203],{"nctId":1204,"briefTitle":1205,"status":687,"phases":1206,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":1209,"conditions":1210,"interventions":1212},"NCT00975962","New Acute Treatment for Stroke - The Effect of Remote PERconditioning",[86],"2011-03","2009-07",120,[1211],"Acute Stroke",[1193],{"trials":1214,"activeCount":95},[],{"trials":1216,"activeCount":95},[],{"intervention":1218,"totalTrials":124,"cells":1219},"CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab",{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1226,"PHASE4":1238,"NA":1240},{"trials":1221,"activeCount":95},[],{"trials":1223,"activeCount":95},[],{"trials":1225,"activeCount":95},[],{"trials":1227,"activeCount":95},[1228],{"nctId":1229,"briefTitle":1230,"status":687,"phases":1231,"primaryCompletion":1232,"completion":1232,"start":1059,"enrollment":1233,"conditions":1234,"interventions":1236},"NCT00646854","Alemtuzumab and CHOP in T-cell Lymphoma",[86],"2016-12-31",136,[1235],"Lymphoma, T-Cell, Peripheral",[1218,1237],"CHOP14 chemotherapy (see specification under Arm B) plus G-CSF",{"trials":1239,"activeCount":95},[],{"trials":1241,"activeCount":95},[],{"intervention":1237,"totalTrials":124,"cells":1243},{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1250,"PHASE4":1256,"NA":1258},{"trials":1245,"activeCount":95},[],{"trials":1247,"activeCount":95},[],{"trials":1249,"activeCount":95},[],{"trials":1251,"activeCount":95},[1252],{"nctId":1229,"briefTitle":1230,"status":687,"phases":1253,"primaryCompletion":1232,"completion":1232,"start":1059,"enrollment":1233,"conditions":1254,"interventions":1255},[86],[1235],[1218,1237],{"trials":1257,"activeCount":95},[],{"trials":1259,"activeCount":95},[],{"intervention":1261,"totalTrials":124,"cells":1262},"Coenzyme Q10",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1280,"PHASE4":1282,"NA":1284},{"trials":1264,"activeCount":95},[],{"trials":1266,"activeCount":95},[],{"trials":1268,"activeCount":95},[1269],{"nctId":1270,"briefTitle":1271,"status":687,"phases":1272,"primaryCompletion":1273,"completion":1273,"start":1274,"enrollment":1275,"conditions":1276,"interventions":1279},"NCT04960215","Coenzyme Q10 as Treatment for Long Term COVID-19",[85],"2022-02-10","2021-05-25",121,[1277,1278],"Covid19","Long Term Covid19",[1261],{"trials":1281,"activeCount":95},[],{"trials":1283,"activeCount":95},[],{"trials":1285,"activeCount":95},[],{"intervention":1287,"totalTrials":124,"cells":1288},"Metoprololsuccinate",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1290,"activeCount":95},[],{"trials":1292,"activeCount":95},[],{"trials":1294,"activeCount":95},[1295],{"nctId":1296,"briefTitle":1297,"status":687,"phases":1298,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":142,"conditions":1301,"interventions":1302},"NCT02076711","Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?",[85],"2015-09","2013-06",[848],[1287],{"trials":1304,"activeCount":95},[],{"trials":1306,"activeCount":95},[],{"trials":1308,"activeCount":95},[],{"intervention":1310,"totalTrials":124,"cells":1311},"Romidepsin",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1313,"activeCount":95},[],{"trials":1315,"activeCount":95},[],{"trials":1317,"activeCount":95},[1318],{"nctId":1319,"briefTitle":1320,"status":687,"phases":1321,"primaryCompletion":1322,"completion":1323,"start":1324,"enrollment":845,"conditions":1325,"interventions":1327},"NCT03041012","Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART",[85],"2021-08-20","2022-12-30","2017-01-20",[1326],"Hiv",[1310,1328,1329],"3BNC117","Antiretrovirals",{"trials":1331,"activeCount":95},[],{"trials":1333,"activeCount":95},[],{"trials":1335,"activeCount":95},[],{"intervention":1328,"totalTrials":124,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1339,"activeCount":95},[],{"trials":1341,"activeCount":95},[],{"trials":1343,"activeCount":95},[1344],{"nctId":1319,"briefTitle":1320,"status":687,"phases":1345,"primaryCompletion":1322,"completion":1323,"start":1324,"enrollment":845,"conditions":1346,"interventions":1347},[85],[1326],[1310,1328,1329],{"trials":1349,"activeCount":95},[],{"trials":1351,"activeCount":95},[],{"trials":1353,"activeCount":95},[],{"intervention":1329,"totalTrials":124,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1357,"activeCount":95},[],{"trials":1359,"activeCount":95},[],{"trials":1361,"activeCount":95},[1362],{"nctId":1319,"briefTitle":1320,"status":687,"phases":1363,"primaryCompletion":1322,"completion":1323,"start":1324,"enrollment":845,"conditions":1364,"interventions":1365},[85],[1326],[1310,1328,1329],{"trials":1367,"activeCount":95},[],{"trials":1369,"activeCount":95},[],{"trials":1371,"activeCount":95},[],{"intervention":1373,"totalTrials":124,"cells":1374},"Norditropin SimpleXx",{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1376,"activeCount":95},[],{"trials":1378,"activeCount":95},[],{"trials":1380,"activeCount":95},[1381],{"nctId":1382,"briefTitle":1383,"status":687,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1390},"NCT01090778","Diurnal Variation of Exogenous Peptides (GH Puls\u002FJurgita I)",[85],"2011-12","2010-10",8,[1389],"Growth Hormone Deficiency",[1373],{"trials":1392,"activeCount":95},[],{"trials":1394,"activeCount":95},[],{"trials":1396,"activeCount":95},[],{"intervention":1398,"totalTrials":124,"cells":1399},"ZD4054",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1401,"activeCount":95},[],{"trials":1403,"activeCount":95},[],{"trials":1405,"activeCount":95},[1406],{"nctId":1407,"briefTitle":1408,"status":969,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1416},"NCT01000948","A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer",[85],"2011-07","2009-10",24,[1414,1415],"Prostate Cancer","Metastasis",[1398],{"trials":1418,"activeCount":95},[],{"trials":1420,"activeCount":95},[],{"trials":1422,"activeCount":95},[],{"intervention":1424,"totalTrials":124,"cells":1425},"Insulin Aspart 100 IE\u002Fml",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1427,"activeCount":95},[],{"trials":1429,"activeCount":95},[],{"trials":1431,"activeCount":95},[1432],{"nctId":1433,"briefTitle":1434,"status":687,"phases":1435,"primaryCompletion":1436,"completion":1437,"start":1438,"enrollment":691,"conditions":1439,"interventions":1441},"NCT01510093","Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)",[85],"2012-12","2013-01","2012-05",[1440],"Type 2 Diabetes Mellitus",[1424],{"trials":1443,"activeCount":95},[],{"trials":1445,"activeCount":95},[],{"trials":1447,"activeCount":95},[],{"intervention":1449,"totalTrials":124,"cells":1450},"RGRN-305",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1470},{"trials":1452,"activeCount":95},[],{"trials":1454,"activeCount":95},[1455],{"nctId":1456,"briefTitle":1457,"status":687,"phases":1458,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":545,"conditions":1461,"interventions":1463},"NCT05286567","A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.",[84],"2022-08-29","2021-09-01",[1462],"Hidradenitis Suppurativa",[1449],{"trials":1465,"activeCount":95},[],{"trials":1467,"activeCount":95},[],{"trials":1469,"activeCount":95},[],{"trials":1471,"activeCount":95},[],{"intervention":1473,"totalTrials":124,"cells":1474},"CUDC-305",{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1476,"activeCount":95},[],{"trials":1478,"activeCount":95},[1479],{"nctId":1480,"briefTitle":1481,"status":1014,"phases":1482,"primaryCompletion":1483,"completion":1181,"start":1484,"enrollment":1485,"conditions":1486,"interventions":1487},"NCT03675542","The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.",[84],"2019-11-01","2018-11-01",16,[250],[1473],{"trials":1489,"activeCount":95},[],{"trials":1491,"activeCount":95},[],{"trials":1493,"activeCount":95},[],{"trials":1495,"activeCount":95},[],{"intervention":1497,"totalTrials":124,"cells":1498},"Vancomycin",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1500,"activeCount":95},[],{"trials":1502,"activeCount":95},[1503],{"nctId":1504,"briefTitle":1505,"status":1506,"phases":1507,"primaryCompletion":1436,"completion":1508,"start":1509,"enrollment":95,"conditions":1510,"interventions":1512},"NCT00925093","Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection","WITHDRAWN",[84],"2013-12","2011-09",[1511],"Neurosurgery",[1497,1513,1514],"Teicoplanin","Linezolid",{"trials":1516,"activeCount":95},[],{"trials":1518,"activeCount":95},[],{"trials":1520,"activeCount":95},[],{"trials":1522,"activeCount":95},[],{"intervention":1513,"totalTrials":124,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1526,"activeCount":95},[],{"trials":1528,"activeCount":95},[1529],{"nctId":1504,"briefTitle":1505,"status":1506,"phases":1530,"primaryCompletion":1436,"completion":1508,"start":1509,"enrollment":95,"conditions":1531,"interventions":1532},[84],[1511],[1497,1513,1514],{"trials":1534,"activeCount":95},[],{"trials":1536,"activeCount":95},[],{"trials":1538,"activeCount":95},[],{"trials":1540,"activeCount":95},[],{"intervention":1514,"totalTrials":124,"cells":1542},{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1557},{"trials":1544,"activeCount":95},[],{"trials":1546,"activeCount":95},[1547],{"nctId":1504,"briefTitle":1505,"status":1506,"phases":1548,"primaryCompletion":1436,"completion":1508,"start":1509,"enrollment":95,"conditions":1549,"interventions":1550},[84],[1511],[1497,1513,1514],{"trials":1552,"activeCount":95},[],{"trials":1554,"activeCount":95},[],{"trials":1556,"activeCount":95},[],{"trials":1558,"activeCount":95},[],{"intervention":1560,"totalTrials":124,"cells":1561},"Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor",{"EARLY_PHASE1":1562,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1563,"activeCount":95},[1564],{"nctId":1565,"briefTitle":1566,"status":687,"phases":1567,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":10,"conditions":1570,"interventions":1572},"NCT06955650","First-in-man Imaging of a New PET Radiotracer for Oxytocin Receptors",[83],"2022-06-30","2021-04-30",[1571],"Pain, Face",[1560],{"trials":1574,"activeCount":95},[],{"trials":1576,"activeCount":95},[],{"trials":1578,"activeCount":95},[],{"trials":1580,"activeCount":95},[],{"trials":1582,"activeCount":95},[],{"intervention":1584,"totalTrials":1585,"cells":1586},"Metformin",4,{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1601,"PHASE4":1603,"NA":1614},{"trials":1588,"activeCount":95},[],{"trials":1590,"activeCount":95},[],{"trials":1592,"activeCount":95},[1593],{"nctId":1594,"briefTitle":1595,"status":687,"phases":1596,"primaryCompletion":1597,"completion":1597,"start":1324,"enrollment":569,"conditions":1598,"interventions":1600},"NCT02810132","Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure",[85],"2018-02-14",[1599],"Heart Failure, Systolic",[1584],{"trials":1602,"activeCount":95},[],{"trials":1604,"activeCount":95},[1605],{"nctId":1606,"briefTitle":1607,"status":1014,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1613},"NCT02797340","Metformin Pharmacokinetics in Patients With Chronic and Acute Heart Failure",[87],"2018-04-30","2016-01-11",110,[1599],[1584],{"trials":1615,"activeCount":95},[1616,1624],{"nctId":1617,"briefTitle":1618,"status":1014,"phases":1619,"enrollment":1620,"conditions":1621,"interventions":1623},"NCT00319293","Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome",[88],20,[1622],"Polycystic Ovary Syndrome",[1584],{"nctId":1625,"briefTitle":1626,"status":1014,"phases":1627,"completion":1628,"start":1629,"enrollment":108,"conditions":1630,"interventions":1631},"NCT00317928","Efficacy of Metformin in PCOS: Metabolic and Hormonal Factors",[88],"2004-09","2001-08",[1622],[1584],{"intervention":1633,"totalTrials":124,"cells":1634},"Alutard phleum pratense subcutaneous immunotherapy",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1636,"activeCount":95},[],{"trials":1638,"activeCount":95},[],{"trials":1640,"activeCount":95},[],{"trials":1642,"activeCount":95},[],{"trials":1644,"activeCount":95},[],{"trials":1646,"activeCount":95},[1647],{"nctId":1648,"briefTitle":1649,"status":687,"phases":1650,"primaryCompletion":1651,"completion":1652,"start":1653,"enrollment":535,"conditions":1654,"interventions":1656},"NCT01085526","Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis",[88],"2014-07","2014-09","2010-02",[1655],"Allergic Rhinoconjunctivitis",[1633,1657],"Alutard phl prat",{"intervention":1657,"totalTrials":124,"cells":1659},{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1668,"NA":1670},{"trials":1661,"activeCount":95},[],{"trials":1663,"activeCount":95},[],{"trials":1665,"activeCount":95},[],{"trials":1667,"activeCount":95},[],{"trials":1669,"activeCount":95},[],{"trials":1671,"activeCount":95},[1672],{"nctId":1648,"briefTitle":1649,"status":687,"phases":1673,"primaryCompletion":1651,"completion":1652,"start":1653,"enrollment":535,"conditions":1674,"interventions":1675},[88],[1655],[1633,1657],{"intervention":1677,"totalTrials":124,"cells":1678},"GLP-1",{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1680,"activeCount":95},[],{"trials":1682,"activeCount":95},[],{"trials":1684,"activeCount":95},[],{"trials":1686,"activeCount":95},[],{"trials":1688,"activeCount":95},[],{"trials":1690,"activeCount":95},[1691],{"nctId":1692,"briefTitle":1693,"status":687,"phases":1694,"completion":1695,"start":1696,"enrollment":1620,"conditions":1697,"interventions":1699},"NCT00264199","Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure",[88],"2007-12","2005-12",[1698],"Heart Failure, Congestive",[1677],{"intervention":1701,"totalTrials":124,"cells":1702},"Asparaginase",{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1709,"PHASE4":1711,"NA":1713},{"trials":1704,"activeCount":95},[],{"trials":1706,"activeCount":95},[],{"trials":1708,"activeCount":95},[],{"trials":1710,"activeCount":95},[],{"trials":1712,"activeCount":95},[],{"trials":1714,"activeCount":95},[1715],{"nctId":1716,"briefTitle":1717,"status":687,"phases":1718,"primaryCompletion":1719,"completion":1720,"start":645,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT04187248","The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008",[],"2016-02-28","2017-03-01",1248,[19],[1701],{"intervention":1725,"totalTrials":124,"cells":1726},"Interferon and ribavirin",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1728,"activeCount":95},[],{"trials":1730,"activeCount":95},[],{"trials":1732,"activeCount":95},[],{"trials":1734,"activeCount":95},[],{"trials":1736,"activeCount":95},[],{"trials":1738,"activeCount":95},[1739],{"nctId":1740,"briefTitle":1741,"status":687,"phases":1742,"primaryCompletion":1743,"completion":1743,"start":1744,"enrollment":225,"conditions":1745,"interventions":1750},"NCT00788918","Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV\u002FCNS)",[88],"2012-11","2008-11",[1746,1747,1748,1749],"Hepatitis C, Chronic","Cognition Disorders","Fatigue Syndrome, Chronic","Major Depressive Disorder",[1725],{"intervention":1752,"totalTrials":124,"cells":1753},"Aspirin 75mg",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1755,"activeCount":95},[],{"trials":1757,"activeCount":95},[],{"trials":1759,"activeCount":95},[],{"trials":1761,"activeCount":95},[],{"trials":1763,"activeCount":95},[],{"trials":1765,"activeCount":95},[1766],{"nctId":1767,"briefTitle":1768,"status":1014,"phases":1769,"primaryCompletion":716,"completion":716,"start":1770,"enrollment":1771,"conditions":1772,"interventions":1775},"NCT03583229","Coronary Artery Disease After Heart Transplantation",[88],"2016-10-13",70,[1773,1774],"Coronary Artery Disease in Transplanted Heart (Diagnosis)","Platelet Dysfunction",[1752],{"intervention":1777,"totalTrials":124,"cells":1778},"Lisdexamfetamine",{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1787,"NA":1789},{"trials":1780,"activeCount":95},[],{"trials":1782,"activeCount":95},[],{"trials":1784,"activeCount":95},[],{"trials":1786,"activeCount":95},[],{"trials":1788,"activeCount":95},[],{"trials":1790,"activeCount":95},[1791],{"nctId":1792,"briefTitle":1793,"status":1014,"phases":1794,"primaryCompletion":1795,"completion":1796,"start":1797,"enrollment":1798,"conditions":1799,"interventions":1803},"NCT04727476","The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders",[],"2021-08-10","2022-05-01","2021-01-19",413,[1800,1801,1802],"Attention Deficit Disorder","Attention Deficit Hyperactivity Disorder","Hyperkinetic Disorder",[1777],{"intervention":1805,"totalTrials":124,"cells":1806},"Discontinue alendronate",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1808,"activeCount":95},[],{"trials":1810,"activeCount":95},[],{"trials":1812,"activeCount":95},[],{"trials":1814,"activeCount":95},[],{"trials":1816,"activeCount":95},[],{"trials":1818,"activeCount":95},[1819],{"nctId":1820,"briefTitle":1821,"status":687,"phases":1822,"primaryCompletion":1823,"completion":1823,"start":1824,"enrollment":1825,"conditions":1826,"interventions":1827},"NCT03051620","Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate",[],"2019-01-31","2017-02-01",142,[144],[1805],{"intervention":1829,"totalTrials":124,"cells":1830},"Pembrolizumab",{"EARLY_PHASE1":1831,"PHASE1":1833,"PHASE2":1835,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1832,"activeCount":95},[],{"trials":1834,"activeCount":95},[],{"trials":1836,"activeCount":95},[],{"trials":1838,"activeCount":95},[],{"trials":1840,"activeCount":95},[],{"trials":1842,"activeCount":95},[1843],{"nctId":1844,"briefTitle":1845,"status":687,"phases":1846,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":142,"conditions":1850,"interventions":1852},"NCT03197636","Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients",[],"2021-11-01","2022-02-01","2017-08-11",[1851],"Malignant Melanoma",[1829],{"intervention":1854,"totalTrials":124,"cells":1855},"TNF-alpha",{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1857,"activeCount":95},[],{"trials":1859,"activeCount":95},[],{"trials":1861,"activeCount":95},[],{"trials":1863,"activeCount":95},[],{"trials":1865,"activeCount":95},[],{"trials":1867,"activeCount":95},[1868],{"nctId":1869,"briefTitle":1870,"status":687,"phases":1871,"primaryCompletion":1437,"completion":1437,"start":1872,"enrollment":1412,"conditions":1873,"interventions":1875},"NCT01452958","Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on Central Nervous System (CNS) Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?",[88],"2010-06",[32,1874],"Glucose Metabolism Disorders",[1854,1876],"Endotoxin",{"intervention":1876,"totalTrials":124,"cells":1878},{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1880,"activeCount":95},[],{"trials":1882,"activeCount":95},[],{"trials":1884,"activeCount":95},[],{"trials":1886,"activeCount":95},[],{"trials":1888,"activeCount":95},[],{"trials":1890,"activeCount":95},[1891],{"nctId":1869,"briefTitle":1870,"status":687,"phases":1892,"primaryCompletion":1437,"completion":1437,"start":1872,"enrollment":1412,"conditions":1893,"interventions":1894},[88],[32,1874],[1854,1876],{"intervention":1896,"totalTrials":124,"cells":1897},"IV crystalloid fluid bolus",{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1902,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1899,"activeCount":95},[],{"trials":1901,"activeCount":95},[],{"trials":1903,"activeCount":95},[],{"trials":1905,"activeCount":95},[],{"trials":1907,"activeCount":95},[],{"trials":1909,"activeCount":95},[1910],{"nctId":1911,"briefTitle":1912,"status":969,"phases":1913,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":91,"conditions":1916,"interventions":1920},"NCT04198168","The Predictive Performance of Renal Ultrasound on Changes in Renal Clearance",[],"2020-11-30","2020-01-01",[1917,1918,1919],"Acute Kidney Injury","Hypoperfusion","Fluid Overload",[1896],{"intervention":1922,"totalTrials":124,"cells":1923},"L-DOPA",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1925,"activeCount":95},[],{"trials":1927,"activeCount":95},[],{"trials":1929,"activeCount":95},[],{"trials":1931,"activeCount":95},[],{"trials":1933,"activeCount":95},[],{"trials":1935,"activeCount":95},[1936],{"nctId":1937,"briefTitle":1938,"status":1014,"phases":1939,"primaryCompletion":1940,"completion":1940,"start":1941,"enrollment":1942,"conditions":1943,"interventions":1945},"NCT02578849","Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia",[],"2016-01","2012-01",45,[1944],"Parkinson´s Disease",[1922],{"intervention":1947,"totalTrials":124,"cells":1948},"Weak steroid",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1950,"activeCount":95},[],{"trials":1952,"activeCount":95},[],{"trials":1954,"activeCount":95},[],{"trials":1956,"activeCount":95},[],{"trials":1958,"activeCount":95},[],{"trials":1960,"activeCount":95},[1961],{"nctId":1962,"briefTitle":1963,"status":1506,"phases":1964,"primaryCompletion":1965,"start":1965,"enrollment":95,"conditions":1966,"interventions":1971},"NCT01682421","Topical Steroid Treatment After Posterior Lamellar Corneal Transplantation",[88],"2012-09",[1967,1968,1969,1970],"Endothelial Dystrophy","Secondary Bullous Keratopathy","Posterior Lamellar Keratoplasty","Descemet's Stripping Endothelial Keratoplasty",[1947,1972],"Potent steroid",{"intervention":1972,"totalTrials":124,"cells":1974},{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1976,"activeCount":95},[],{"trials":1978,"activeCount":95},[],{"trials":1980,"activeCount":95},[],{"trials":1982,"activeCount":95},[],{"trials":1984,"activeCount":95},[],{"trials":1986,"activeCount":95},[1987],{"nctId":1962,"briefTitle":1963,"status":1506,"phases":1988,"primaryCompletion":1965,"start":1965,"enrollment":95,"conditions":1989,"interventions":1990},[88],[1967,1968,1969,1970],[1947,1972],{"intervention":1992,"totalTrials":124,"cells":1993},"High intensity lipid lowering",{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1995,"activeCount":95},[],{"trials":1997,"activeCount":95},[],{"trials":1999,"activeCount":95},[],{"trials":2001,"activeCount":95},[],{"trials":2003,"activeCount":95},[],{"trials":2005,"activeCount":95},[2006],{"nctId":2007,"briefTitle":2008,"status":687,"phases":2009,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2013,"interventions":2014},"NCT05368545","Influence of Lipid Lowering on Impaired Coronary Flow",[88],"2024-04-17","2020-05-15",109,[16],[1992],{"intervention":2016,"totalTrials":124,"cells":2017},"Degarelix",{"EARLY_PHASE1":2018,"PHASE1":2020,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2019,"activeCount":95},[],{"trials":2021,"activeCount":95},[],{"trials":2023,"activeCount":95},[],{"trials":2025,"activeCount":95},[],{"trials":2027,"activeCount":95},[],{"trials":2029,"activeCount":95},[2030],{"nctId":2031,"briefTitle":2032,"status":1014,"phases":2033,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":845,"conditions":2037,"interventions":2040},"NCT04282876","Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer",[],"2024-02-01","2025-10-31","2020-02-19",[2038,2039,24],"Bladder Cancer","Radiation Therapy Complication",[2016],{"intervention":2042,"totalTrials":124,"cells":2043},"USP endotoxin",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2045,"activeCount":95},[],{"trials":2047,"activeCount":95},[],{"trials":2049,"activeCount":95},[],{"trials":2051,"activeCount":95},[],{"trials":2053,"activeCount":95},[],{"trials":2055,"activeCount":95},[2056],{"nctId":2057,"briefTitle":2058,"status":687,"phases":2059,"primaryCompletion":2060,"completion":2060,"start":2061,"enrollment":1387,"conditions":2062,"interventions":2064},"NCT00929136","Peripheral Effects of Endotoxin on Insulin Resistance",[88],"2010-05","2009-06",[2063],"Healthy",[2042],{"intervention":2066,"totalTrials":124,"cells":2067},"Gabapentin group",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2069,"activeCount":95},[],{"trials":2071,"activeCount":95},[],{"trials":2073,"activeCount":95},[],{"trials":2075,"activeCount":95},[],{"trials":2077,"activeCount":95},[],{"trials":2079,"activeCount":95},[2080],{"nctId":2081,"briefTitle":2082,"status":1014,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2085,"enrollment":717,"conditions":2086,"interventions":2088},"NCT00572208","Gabapentin for Postoperative Pain Management After Cardiac Surgery With Median Sternotomy",[88],"2009-02","2008-01",[2087],"Pain, Postoperative",[2066],{"intervention":2090,"totalTrials":124,"cells":2091},"erythropoietin",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2093,"activeCount":95},[],{"trials":2095,"activeCount":95},[],{"trials":2097,"activeCount":95},[],{"trials":2099,"activeCount":95},[],{"trials":2101,"activeCount":95},[],{"trials":2103,"activeCount":95},[2104],{"nctId":2105,"briefTitle":2106,"status":687,"phases":2107,"primaryCompletion":2108,"start":2109,"enrollment":691,"conditions":2110,"interventions":2112},"NCT00793767","Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration",[88],"2009-04","2009-01",[2111],"Insulin Sensitivity",[2090],{"intervention":2114,"totalTrials":124,"cells":2115},"Alectinib",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2117,"activeCount":95},[],{"trials":2119,"activeCount":95},[],{"trials":2121,"activeCount":95},[],{"trials":2123,"activeCount":95},[],{"trials":2125,"activeCount":95},[],{"trials":2127,"activeCount":95},[2128],{"nctId":2129,"briefTitle":2130,"status":1014,"phases":2131,"primaryCompletion":1568,"completion":2132,"start":2133,"enrollment":142,"conditions":2134,"interventions":2139},"NCT04708639","Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients",[],"2025-06-30","2019-06-19",[2135,2136,2137,2138],"Lung Cancer","ALK Gene Mutation","Resistance, Disease","Mutation",[2114]]